Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34 results about "Secretory IgA" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Secretory Immunoglobulin A (Secretory IgA, or SIgA) is important in protecting the mucosal surfaces of the body. The mucosal surfaces are the first line of protection, as they play a role in defending the body against pathogenic molecules.
HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
A composition for treating a subject is provided. The composition includes dimeric or polymeric IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the sequential modification of monomeric IgA with J chain and secretory component to form a dimeric or polymeric IgA therapeutic. The dimeric or polymeric IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microeneapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.
Owner:SIMON MICHAEL R
Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases
A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided wherein dimeric or polymeric IgA is modified with secretory component to form a dimeric or polymeric secretory IgA therapeutic. The dimeric or polymeric secretory IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.
Owner:SIMON MICHAEL R
Process for producing milk fractions rich in secretory immunoglobulins
InactiveUS20110130545A1Yield easilyHigh yieldMilk preparationMetabolism disorderNasal cavityFiltration
The present invention concerns a process for producing compositions that are rich in secretory IgA (S-IgA) by fractionating milk containing S-IgA. Such compositions may be used in particular for treating and / or preventing infections and / or inflammation of the mucosal surfaces, e.g. the gastro-intestinal tract, urogenital tract, respiratory tract, nasal cavity or oral cavity, treating and / or preventing obesity and related diseases, or treating and / or preventing food allergies in subjects in need of such treatment. Briefly stated, the current invention provides a process for producing milk fractions rich in secretory Immunoglobulin A, using one or more microporous membrane filtration steps. A preferred protocol of the present process involves de-fatting, micro-filtration and ultrafiltration-concentration through a number of diafiltration cycles. The process of the invention, apart from the unexpectedly high yields achievable, offers advantages which are of particular interest in view of the scalability, application in existing diary factories and controllability of process parameters influencing the S-IgA quality and stability.
Owner:W HEALTH LP
Method for the detection of stress biomarkers including cortisol by fluorescence polarization
The inventive subject matter relates to a competitive method measuring stress biomarkers in bodily fluids including serum, urine and oral fluids including saliva. The inventive method measures biomarkers including cortisol, melatonin and secretory IgA by fluorescence polarization fluorescence lifetime analysis or fluorescence resonance energy transfer.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY
Fusion protein, fusion protein preparation method and porcine oral vaccine or medicine
ActiveCN106188307AEffective protectionAvoid degradationSsRNA viruses positive-senseAntibody mimetics/scaffoldsPathogenSecretory IgA
The invention provides a fusion protein and a porcine oral vaccine or medicine. The fusion protein is obtained by fusion of all or part of fragments of brucella outer membrane protein (OMP16) and porcine epidemic diarrhea virus S protein (PEDV-S). The porcine oral vaccine or medicine is obtained by steps: loading the fusion protein into a lactobacillus expression vector, transforming the lactobacillus expression vector into a Lactobacillus casei standard strain, and culturing the strain. The porcine oral vaccine is capable of effectively stimulating intestinal local immune cells to generate secretory IgA and is applicable to elimination of intestinal mucosal pathogens such as bacteria, viruses and parasites, and defects that conventional vaccination causes stress and antibodies fail to reach positions of the pathogens are avoided. In addition, due to adoption of an active lactobacillus vector system, possibility of degradation and ineffectiveness of inactivated vaccines before reaching small intestine mucosa is avoided. The porcine oral vaccine and the medicine are effective in prevention and treatment of porcine epidemic diarrhea virus infection.
Owner:CHANGSHA LVYE BIOTECHNOLOGY CO LTD
SYNTHESIS OF HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of dimeric or polymeric IgA with secretory component to form a dimeric or polymeric secretory IgA therapeutic. The dimeric or polymeric secretory IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.
Owner:SIMON MICHAEL R
Non-classical secretory protein and application thereof to protein secretory expression
The invention relates to heterologous protein secreted in bacillus subtilis in a non-classical path and application thereof to protein secretory expression. Carrying no signal peptide or secretory signals, D-allulose3-epimerase RDPE from Ruminococcus sp.5-139B-FAA can be secreted out of cells in quantity; it is proved through experiments that RDPE is not secreted in an Sec or Tat path or leaked out of the cells due to cell autolysis and lysis. Therefore RDPE is non-classical secretory protein in the bacillus subtilis. RDPE is respectively fused with 18 kinds of target protein, an attempt is made to use RDPE as export signals for achieving secretory expression of the target protein, 16 kinds of fused protein are obviously expressed in the cells, 9 kinds of fused protein are successfully secreted out of the cells, and the secretion level of two kinds of fused protein accounts for more than 50% of the corresponding total protein. Therefore, a new strategy for achieving protein secretory expression in the bacillus subtilis is developed.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Plant lactobacillus composition and its application in strengthening intestinal immunobarrier
The present invention relates to a kind of composition containing plant lactobacillus LP-Onlly strain and its application in strengthening intestinal immunobarrier. The composition of the present invention can intervene the homing of intestinal lymphocyte, control the number of intestinal tract secretive IgA and intestinal lymphocyte, lower the endotoxin level, improve intestinal tract immunobarrier and prevent damage of intestinal tract immunobarrier caused by hunger, malnutrition, infection, etc, and prevent and treat intestinal inflammation, infectious diseases and immune disorder diseases.
Owner:SHANGHAI JIAODA ONLLY CO LTD
A non-canonical secretory protein and its application in protein secretory expression
The invention relates to heterologous protein secreted in bacillus subtilis in a non-classical path and application thereof to protein secretory expression. Carrying no signal peptide or secretory signals, D-allulose3-epimerase RDPE from Ruminococcus sp.5-139B-FAA can be secreted out of cells in quantity; it is proved through experiments that RDPE is not secreted in an Sec or Tat path or leaked out of the cells due to cell autolysis and lysis. Therefore RDPE is non-classical secretory protein in the bacillus subtilis. RDPE is respectively fused with 18 kinds of target protein, an attempt is made to use RDPE as export signals for achieving secretory expression of the target protein, 16 kinds of fused protein are obviously expressed in the cells, 9 kinds of fused protein are successfully secreted out of the cells, and the secretion level of two kinds of fused protein accounts for more than 50% of the corresponding total protein. Therefore, a new strategy for achieving protein secretory expression in the bacillus subtilis is developed.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
Secretory iga compositions, methods of making and methods of use thereof
ActiveUS20140193395A1Increase probabilityImprove feeding efficiencyDigestive systemImmunoglobulins against animals/humansIntestinal structureBiotechnology
Described herein is secretory IgA isolated from the intestinal luminal fluid and intestinal mucosal of animals such as pigs and cows. Also included are methods of isolating secretory IgA. The secretory IgA is useful in food compositions such as animal and human food compositions as well as pharmaceutical compositions to increase growth rate, improve feed efficiency, reduce gastrointestinal inflammation, reduce a risk of gastrointestinal infection in the animal, or a combination thereof.
Owner:WISCONSIN ALUMNI RES FOUND
METHODS OF USE OF SECRETORY IgA
ActiveUS20150086534A1Preventing and treating inflammationAntibody ingredientsImmunoglobulinsSecretory IgAAnatomy
Described herein are methods of preventing and / or treating inflammation in a barrier surface structure in an individual in need thereof by orally administering to the individual an anti-inflammatory amount of secretory IgA.
Owner:WISCONSIN ALUMNI RES FOUND
Secretory IgA and IgG Antibody Inducer
InactiveUS20100158946A1Efficient productionProvide protectionSsRNA viruses negative-senseOrganic active ingredientsSerum igeAdjuvant
A nasal vaccine is provided which induces the production of secretory IgA and IgG antibodies specific for flaviviruses, including hantaviruses. Furthermore, a method for providing protection against infection with flaviviruses by induces of the secretory IgA and IgG antibodies is also provided. The nasal vaccine includes an inactivated antigen of a flavivirus and poly(I:C) or a ceramified powder of surf clam shells as an adjuvant. The vaccine effectively induces secretion of IgA antibodies in the nasal mucosa and serum IgG antibody responses. Also provided is a method for inducing flavivirus-specific IgA and IgG antibodies, including administering an inactivated antigen of a flavivirus and poly(I:C) or a ceramified powder of surf clam shells as an adjuvant to the mucosa of a respiratory tract.
Owner:MORIYAMA MASAMI
Antigen chimera, antigen composition, vaccine, method of preparing the same and cassette thereof
ActiveUS20160368951A1Improving immunogenicityIncrease volumeAntibacterial agentsAntibody mimetics/scaffoldsEscherichia coliPentamer
The present invention provides an antigen chimera, comprising: a fusion protein of an antigen and a mucosal immune adjuvant protein monomer capable of forming a multimer; and the mucosal immune adjuvant protein monomer capable of forming the multimer; wherein the mucosal immune adjuvant protein monomer capable of forming the multimer is one selected from cholera toxin B subunit (CTB) and E. coli heat-labile enterotoxin B subunit (LTB), the multimer is a pentamer, and in the chimera the molar ratio between the fusion protein and the mucosal immune adjuvant protein monomer capable of forming multimers is 1:4. In the present invention, a characteristic that a mucosal immune adjuvant protein can form a pentamer is used to form a chimeric structure, so as to form an antigen having a higher potency. Moreover, a mucosal immune adjuvant protein is used to improve an immune effect, so as to improve an effect of enhancing antigen immunogenicity. In addition, the chimeric protein antigen formed with the recombined antigen of the present invention stimulates a mucous membrane to produce secretory IgA and induce the occurrence of mucosal immunity.
Owner:SHANGHAI UNITED CELL BIOTECH
Co-expression cell of secretory anti-immune checkpoint antibody and tEGFR molecule and application thereof
InactiveCN109750067AAchieve and facilitate specific killingImprove securityMicroorganism based processesViruses/bacteriophagesTumor cellsReceptor for activated C kinase 1
The invention provides an expression vector, a lentivirus, a transgenic cell, a secretory antibody and a therapeutic composition for treating cancer. The expression vector carries the following nucleic acid molecules: a first nucleic acid molecule, which is used for encoding a secretory immune checkpoint inhibiting molecule fragment; optionally, a second nucleic acid molecule is further carried, wherein the second nucleic acid molecule is used for encoding a non-functional EGFR. The expression vector of the embodiment of the invention is introduced into receptor cells, a secretory anti-immunecheckpoint antibody is efficiently expressed in the receptor cells and secreted outside the cells, and an immune escape mechanism mediated by the immune checkpoint is repressed. When the expression vector of the embodiment of the invention is introduced into the receptor cells, such as lymphocytes, the specific killing of tumor cells by lymphocytes is strong and effective.
Owner:ILIFESEQ LTD CORP
Extraction method of human body secretory IgA, the human body secretory IgA, and O-glycosylation measurement method thereof
InactiveCN106220731AAvoid harmHigh IgA contentImmunoglobulins against animals/humansPeptide preparation methodsProtein CSerum ige
The invention belongs to the technical field of biology and provides an extraction method of human body secretory IgA, the human body secretory IgA, and an O-glycosylation measurement method thereof. The extraction method includes the steps of: firstly extracting oral cavity secretion of human body and centrifuging the oral cavity secretion; treating the oral cavity secretion to separate and purify the human body secretory immune globulin IgA by means of fast protein liquid chromatography with a Jacalin-agarose affinity chromatographic column; and performing the O-glycosylation measurement to the purified IgA. The method, compared with serum extraction, is painless, is convenient and is harmless to human body, and compared with urine IgA extraction, is high in content of the IgA after extraction and purification and is simple in separation and enrichment. The method can be widely applied in medical researching and laboratory researching.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Preparation of pig secretory IgA secretory component and purification and renaturation method of pig secretory IgA secretory component
InactiveCN109180811AReduce manufacturing costImprove renaturation efficiencyImmunoglobulins against animals/humansPeptide preparation methodsBiotechnologySecretory IgA
The invention discloses preparation of a pig secretory IgA secretory component and a purification and renaturation method of the pig secretory IgA secretory component. SIgA is an important index for evaluating the mucosal immunity level of an organism, a secretory component SC is a specific component of an SIgA molecule, and the content of SIgA can be evaluated by virtue of SC proteins. Researching results on different prokaryotic expression vectors and host strains prove that by utilizing pET-28a prokaryotic expression vectors and Rosetta host strains, a large number of SC recombinant proteins can be expressed in vitro, after the SC recombinant proteins are purified and renaturated, the purities of the SC recombinant proteins are high, and the SC recombinant proteins can specifically bound with anti-nature SIgA polyclonal antibodies. The operation is simple, and a large number of the SC proteins with relatively high impurities can be acquired, so that the SC proteins have very good popularization and application values.
Owner:广东海大集团股份有限公司畜牧水产研究中心 +1
Secretory IGA compositions, methods of making and methods of use thereof
ActiveUS9458230B2Reduce inflammationIncrease probabilityDigestive systemImmunoglobulins against animals/humansBiotechnologyGastrointestinal inflammation
Owner:WISCONSIN ALUMNI RES FOUND
Nutritional formula with non-digestible oligosaccharides and non-replicating lactic acid producing bacteria
InactiveCN108697141AHigh activityOrganic active ingredientsUnknown materialsBacteroidesSecretory IgA
A nutritional composition comprises non-digestible oligosaccharideandnon-replicating Bifidobacterium breveand / or Streptococcus thermophilussynergistically stimulates secretory IgA in infants.
Owner:NV NUTRICIA
Co-expression of secretory anti-immune checkpoint antibody, intracellular immune checkpoint inhibiting molecule and tEGFR molecule and application thereof
InactiveCN109750066AAchieve and facilitate specific killingImprove securityAntibody ingredientsViruses/bacteriophagesEffect functionImmune checkpoint molecules
The invention provides an expression vector, a lentivirus, a transgenic cell, a secretory antibody and a therapeutic composition for treating cancer. The expression vector carries the following nucleic acid molecules: (a) a first nucleic acid molecule, which is used for encoding a secretory immune checkpoint inhibiting molecule fragment; (b) a second nucleic acid molecule, which is used for silencing an intracellular immune checkpoint and optionally further carrying a third nucleic acid molecule, wherein the third nucleic acid molecule is used for encoding a non-functional EGFR. The expressionvector of the embodiment of the invention is introduced into receptor cells, a secretory anti-immune checkpoint antibody is efficiently expressed in the receptor cells and secreted outside the cells,meanwhile, the immune checkpoint molecules of the receptor cells are specifically silenced, and an immune escape mechanism mediated by the immune checkpoint is repressed. When the expression vector of the embodiment of the invention is introduced into the receptor cells, such as lymphocytes, the proliferation capacity and the effect function of the lymphocytes are enhanced, and the specific killing of tumor cells is stronger and more effective.
Owner:ILIFESEQ LTD CORP
COMPOSITION COMPRISING SECRETATING IgA AND PROBIOTIC BACTERIA
Owner:SOC DES PROD NESTLE SA
Human medical prophylaxis of coronaviridae pathogenic infection by topical application of immune coronaviridae immunoglobulin a
A method of inhibiting or treating infection by Coronaviridae virus of a susceptible host is provided that includes the administration of immune anti-Coronaviridae secretory IgA having a recombinant secretory component to at least one of tissue of the susceptible host. The administration being prior to, or after the susceptible host is exposed to the Coronaviridae virus. A composition for such administration is also provided.
Owner:OLSON ROBERT SCOTT +1
Secretory immunoglobulin produced by single cells and methods for making and using same
Disclosed is a method of producing secretory Ig molecules. The method comprises transfecting a cell producing an Ig with a polynucleotide encoding an SC to form SC transfected Ig producing cells. Secretory Ig molecules, such as secretory IgA, can be used to treat or prevent infection.
Owner:RGT UNIV OF CALIFORNIA
Antigen chimera, antigen composition, vaccine, method of preparing the same and cassette thereof
ActiveUS10513543B2Improving immunogenicityIncrease volumeAntibacterial agentsBacterial antigen ingredientsPentamerImmunogenicity
The present invention provides an antigen chimera, comprising: a fusion protein of an antigen and a mucosal immune adjuvant protein monomer capable of forming a multimer; and the mucosal immune adjuvant protein monomer capable of forming the multimer; wherein the mucosal immune adjuvant protein monomer capable of forming the multimer is one selected from cholera toxin B subunit (CTB) and E. coli heat-labile enterotoxin B subunit (LTB), the multimer is a pentamer, and in the chimera the molar ratio between the fusion protein and the mucosal immune adjuvant protein monomer capable of forming multimers is 1:4. In the present invention, a characteristic that a mucosal immune adjuvant protein can form a pentamer is used to form a chimeric structure, so as to form an antigen having a higher potency. Moreover, a mucosal immune adjuvant protein is used to improve an immune effect, so as to improve an effect of enhancing antigen immunogenicity. In addition, the chimeric protein antigen formed with the recombined antigen of the present invention stimulates a mucous membrane to produce secretory IgA and induce the occurrence of mucosal immunity.
Owner:SHANGHAI UNITED CELL BIOTECH
A fusion protein, its preparation method and a porcine oral vaccine or medicine
ActiveCN106188307BEffective protectionAvoid degradationSsRNA viruses positive-senseAntibody mimetics/scaffoldsBiologyInactivated vaccine
The invention provides a fusion protein and a porcine oral vaccine or medicine. The fusion protein is obtained by fusion of all or part of fragments of brucella outer membrane protein (OMP16) and porcine epidemic diarrhea virus S protein (PEDV-S). The porcine oral vaccine or medicine is obtained by steps: loading the fusion protein into a lactobacillus expression vector, transforming the lactobacillus expression vector into a Lactobacillus casei standard strain, and culturing the strain. The porcine oral vaccine is capable of effectively stimulating intestinal local immune cells to generate secretory IgA and is applicable to elimination of intestinal mucosal pathogens such as bacteria, viruses and parasites, and defects that conventional vaccination causes stress and antibodies fail to reach positions of the pathogens are avoided. In addition, due to adoption of an active lactobacillus vector system, possibility of degradation and ineffectiveness of inactivated vaccines before reaching small intestine mucosa is avoided. The porcine oral vaccine and the medicine are effective in prevention and treatment of porcine epidemic diarrhea virus infection.
Owner:CHANGSHA LVYE BIOTECHNOLOGY CO LTD
Fermented formula with non-digestible oligosaccharides
PendingCN108882740AHigh activityOrganic active ingredientsUnknown materialsSecretory IgAOligosaccharide
A fermented formula comprising non digestible oligosaccharides synergistically stimulates secretory IgA in infants.
Owner:NV NUTRICIA
Composition for the treatment of antibody deficiencies
PendingUS20210395348A1Sustained releaseEnhanced drug releaseDigestive systemImmunoglobulins against bacteriaSecretory IgAImmunoglobulin A
The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore, SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels, these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response. Accordingly, the invention relates to a composition containing immunoglobulins A (IgA), more particularly secretory IgA, for use by oral administration in the prevention or treatment of antibody deficiencies such as SIgAd (Selective IgA deficiency) or common variable immunodeficiency (CVID) and associated inflammatory diseases.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Genetic engineering subunit oral vaccine for African swine fever virus
ActiveCN114456240AGood effectBacteriaVirus peptidesClassical swine fever virus CSFVStaphylococcus lactis
The invention provides an African swine fever virus genetic engineering subunit oral vaccine, which comprises genetic engineering lactococcus lactis for recombinant expression of African swine fever virus antigen protein, and the antigen protein is ASFV p30 protein with an amino acid sequence of SEQ ID NO: 1, ASFV p54 protein with an amino acid sequence of SEQ ID NO: 3 or ASFV p72 protein with an amino acid sequence of SEQ ID NO: 5. The antigen protein is connected with an Escherichia coli heat-labile enterotoxin B subunit LTB gene protein. The African swine fever virus genetic engineering subunit oral vaccine can effectively stimulate local immune cells of intestinal tracts to generate secretory IgA, stimulate an organism to generate mucosal reaction, and further stimulate the organism to generate cellular immunity and humoral immunity through blood circulation.
Owner:QINGDAO AGRI UNIV
Suppression of antimicrobial protein levels
ActiveUS20190209635A1Pharmaceutical delivery mechanismFungi medical ingredientsTreatment effectSaliva sample
Exercise is a stressor that is known to in some cases suppress antimicrobial protein levels, particularly secretory immunoglobulin type A (IgA). Athletes in the midst of in-season training often demonstrate low levels of sIgA and supplements may enhance post exercise mucosal immune function. A study was conducted where three treatments were administered (botanical spray, botanical drops, placebo) at the onset of 30 minutes of 80% V02 max cycle ergometer exercise. Secretory IgA and Human Alpha Defensin were quantified in saliva samples 30 minutes and 90 minutes post exercise. Analysis revealed a significant treatment effect at 30 min (p=0.030) with post hoc testing revealing a difference between the botanical spray and placebo (p=0.027), but by 90 minutes there was no differences by treatment (p=0.758). Based upon this study, it appears that a single dose of the tested botanical can provide enhanced mucosal immune capability for a short time post exercise.
Owner:UNIVERSITY OF LOUISIANA AT LAFAYETTE
COMPOSITIONS COMPRISING SECRETORY IgA AND PROBIOTICS
PendingUS20220296706A1Promotion of associated health benefitsImprove biological activityAntipyreticMilk immunoglobulinsSecretory IgABiochemistry
The present invention relates to methods for producing compositions comprising secretory IgA and one or more probiotics. In particular, the invention relates to methods for producing compositions in which the secretory IgA and one or more probiotics are associated. The invention also relates to compositions obtainable by the methods and uses of the compositions, for example in reducing or preventing a non-viral infection and / or inflammation.
Owner:SOC DES PROD NESTLE SA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com